1
|
Calas M, Ouattara M, Piquet G, Ziora Z, Bordat Y, Ancelin ML, Escale R, Vial H. Potent Antimalarial Activity of 2-Aminopyridinium Salts, Amidines, and Guanidines. J Med Chem 2007; 50:6307-15. [PMID: 18004799 DOI: 10.1021/jm0704752] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Michèle Calas
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Mahama Ouattara
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Gilles Piquet
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Zyta Ziora
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Y. Bordat
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Marie L. Ancelin
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Roger Escale
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| | - Henri Vial
- Institut des Biomolécules Max Mousseron (IBMM) CNRS UMR 5247, Université Montpellier 1, Faculté de Pharmacie, 15, Avenue C. Flahault, BP 14491, 34093 Montpellier Cedex 5 and Université Montpellier 2, Place E. Bataillon, CP19, 34095 Montpellier Cedex 5, France, Laboratoire de Chimie Thérapeutique et Synthèse de Médicaments, Faculté de Pharmacie, Université dʼAbidjan-Cocody, BP V, 34 Abidjan, Côte dʼIvoire, and Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, CP 107,
| |
Collapse
|
2
|
Abstract
Synthetically produced GRF1-29 (Sermorelin) has an amino acid composition identical to the N-terminal 29 amino acids sequence of the natural hypothalamic GHRH1-44 (Figure 1). It maintains bioactivity in vitro and is almost equally effective in eliciting secretion of endogenous growth hormone in vivo. The main drawbacks associated with the pharmaceutical use of hGRF1-29 relate to its short half-life in plasma, about 10-20 min in humans, which is caused mostly by renal ultrafiltration and enzymatic degradation at the N terminus. PEGylation has been considered as one valid approach to obtain more stable forms of the peptide, with a longer in vivo half-life and ultimately with increased pharmacodynamic response along the somatotropic axis (endogenous GH, IGF-1 levels). Different PEGylated GRF conjugates were obtained and their bioactivity was tested in vitro and in vivo by monitoring endogenous growth hormone (GH) serum levels after intravenous (i.v.) injection in rats, and intravenous and subcutaneous (s.c.) injection in pigs. It was found that GRF-PEG conjugates are able to bind and activate the human GRF receptor, although with different potency. The effect of PEG molecular weight, number of PEG chains bound and position of PEGylation site on GRF activity were investigated. Mono-PEGylated isomers with a PEG5000 polymer chain linked to Lys 12 or Lys 21 residues, showed high biological activity in vitro, which is similar to that of hGRF1-29, and a higher pharmacodynamic response as compared to unmodified GRF molecule.
Collapse
Affiliation(s)
- P Esposito
- Industria Farmaceutica Serono, Drug Delivery Systems, Via Ribes 5, BioIndustry Park del Canavese, 10010 Colleretto Giacosa (TO), Italy.
| | | | | | | | | | | | | |
Collapse
|
3
|
Digilio G, Barbero L, Bracco C, Corpillo D, Esposito P, Piquet G, Traversa S, Aime S. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2. J Am Chem Soc 2003; 125:3458-70. [PMID: 12643708 DOI: 10.1021/ja021264j] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Two novel mono-PEGylated derivatives of hGRF(1-29)-NH(2) [human growth hormone-releasing factor, fragment 1-29] have been synthesized by regio-specific conjugation of Lys(12) or Lys(21) to a monomethoxy-PEG(5000) chain (compounds Lys(12)PEG-GRF and Lys(21)PEG-GRF). The PEG moiety has been covalently linked at the amino group of a norleucine residue via a carbamate bond. The Lys(12)PEG-GRF regioisomer was found to be slightly less active in vitro than both the unmodified peptide and Lys(21)PEG-GRF. To assess whether the differences in the biological activity of the PEGylated analogues could be related to conformational rearrangements induced by the PEG moiety, the structure of these PEGylated derivatives has been worked out (TFE solution) by means of NMR spectroscopy and molecular dynamics. Secondary structure shifts, hydrogen/deuterium exchange kinetics, temperature coefficients of amide protons, and NOE-based molecular models point out that hGRF(1-29)-NH(2), Lys(21)PEG-GRF and Lys(12)PEG-GRF share a remarkably similar pattern of secondary structure. All three compounds adopt an alpha-helix conformation which spans the whole length of the molecule, and which becomes increasingly rigid on going from the N-terminus to the C-terminus. Residues Lys(12) and Lys(21) are enclosed in all the compounds considered into well-defined alpha-helical domains, indicating that PEGylation either at Lys(12) or Lys(21) does not alter the tendency of the peptide to adopt a stable alpha-helix conformation, nor does it induce appreciable conformational mobility in the proximity of the PEGylation sites. No significant variation of the amphiphilic organization of the alpha-helix is observed among the three peptides. Therefore, the different biological activities observed for the PEGylated analogues are not due to conformational effects, but are rather due to sterical hindrance effects. The relationship between the biological activitiy of the mono-PEGylated derivatives and sterical hindrance is discussed in terms of the topology of interaction between hGRF(1-29)-NH(2) and its receptor.
Collapse
Affiliation(s)
- Giuseppe Digilio
- Bioindustry Park del Canavese, Via Ribes 5, I-10010 Colleretto Giacosa (TO), Italy.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Calas M, Ancelin ML, Cordina G, Portefaix P, Piquet G, Vidal-Sailhan V, Vial H. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J Med Chem 2000; 43:505-16. [PMID: 10669577 DOI: 10.1021/jm9911027] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
On the basis of a previous structure-activity relationship study, we identified some essential parameters, e.g. electronegativity and lipophilicity, required for polar head analogues to inhibit Plasmodium falciparum phospholipid metabolism, leading to parasite death. To improve the in vitro antimalarial activity, 36 cationic choline analogues consisting of mono-, bis-, and triquaternary ammonium salts with distinct substituents of increasing lipophilicity were synthesized. For monoquaternary ammonium salts, an increase in the lipophilicity around nitrogen was beneficial for antimalarial activity: IC(50) decreased by 1 order of magnitude from trimethyl to tripropyl substituents. Irrespective of the polar head substitution (methyl, ethyl, hydroxyethyl, pyrrolidinium), increasing the alkyl chain length from 6 to 12 methylene groups always led to increased activity. The highest activity was obtained for the N,N,N-tripropyl-N-dodecyl substitution of nitrogen (IC(50) 33 nM). Beyond 12 methylene groups, the antimalarial activities of the compounds decreased slightly. The structural requirements for bisquaternary ammonium salts in antimalarial activity were very similar to those of monoquaternary ammonium salts, i.e. polar head steric hindrance and lipophilicity around nitrogen (methyl, hydroxyethyl, ethyl, pyrrolidinium, etc.). In contrast, with bisquaternary ammonium salts, increasing the lipophilicity of the alkyl chain between the two nitrogen atoms (from 5 to 21 methylene groups) constantly and dramatically increased the activity. Most of these duplicated molecules had activity around 1 nM, and the most lipophilic compound synthesized exhibited an IC(50) as low as 3 pM (21 methylene groups). Globally, this oriented synthesis produced 28 compounds out of 36 with an IC(50) lower than 1 microM, and 9 of them had an IC(50) in the nanomolar range, with 1 compound in the picomolar range. This indicates that developing a pharmacological model for antimalarial compounds through choline analogues is a promising strategy.
Collapse
Affiliation(s)
- M Calas
- Laboratoire des Aminoacides, Peptides et Proteines, CNRS, UMR 5810, CP 22, Université de Montpellier II, Place E. Bataillon, 34095 Montpellier Cedex 5, France.
| | | | | | | | | | | | | |
Collapse
|
6
|
Ancelin ML, Vial HJ, Calas M, Giral L, Piquet G, Rubi E, Thomas A, Peters W, Slomianny C, Herrera S. Present development concerning antimalarial activity of phospholipid metabolism inhibitors with special reference to in vivo activity. Mem Inst Oswaldo Cruz 1994; 89 Suppl 2:85-90. [PMID: 7565139 DOI: 10.1590/s0074-02761994000600020] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The systematic screening of more than 250 molecules against Plasmodium falciparum in vitro has previously shown that interfering with phospholipid metabolism is lethal to the malaria parasite. These compounds act by impairing choline transport in infected erythrocytes, resulting in phosphatidylcholine de novo biosynthesis inhibition. A thorough study was carried out with the leader compound G25, whose in vitro IC50 is 0.6 nM. It was very specific to mature parasites (trophozoïtes) as determined in vitro with P. falciparum and in vivo with P. chabaudi -infected mice. This specificity corresponds to the most intense phase of phospholipid biosynthesis activity during the parasite cycle, thus corroborating the mechanism of action. The in vivo antimalarial activity (ED50) against P. chabaudi was 0.03 mg/kg, and a similar sensitivity was obtained with P. vinckei petteri, when the drug was intraperitoneally administered in a 4 day suppressive test. In contrast, P. berghei was revealed as less sensitive (3- to 20-fold, depending on the P. berghei-strain). This difference in activity could result either from the degree of synchronism of every strain, their invasion preference for mature or immature red blood cells or from an intrinsically lower sensitivity of the P. berghei strain to G25. Irrespective of the mode of administration, G25 had the same therapeutic index (lethal dose 50 (LD50)/ED50) but the dose to obtain antimalarial activity after oral treatment was 100-fold higher than after intraperitoneal (or subcutaneous) administration. This must be related to the low intestinal absorption of these kind of compounds.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M L Ancelin
- CNRS URA 1856, Université Montpellier II, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|